Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.

被引：0
|
作者：
Tanaka, Kazuhiro
Machida, Ryunosuke
Kawai, Akira
Nakayama, Robert
Tsukushi, Satoshi
Asanuma, Kunihiro
Matsumoto, Yoshihiro
Hiraga, Hiroaki
Hiraoka, Koji
Watanuki, Munenori
Yonemoto, Tsukasa
Abe, Satoshi
Katagiri, Hirohisa
Nishida, Yoshihiro
Nagano, Akihito
Suehara, Yoshiyuki
Kataoka, Tomoko
Fukuda, Haruhiko
Ozaki, Toshifumi
Iwamoto, Yukihide
机构：
[1] Oita Univ, Fac Med, Oita, Japan
[2] Natl Canc Ctr, Operat Off, Japan Clin Oncol Grp, Data Ctr, Tokyo, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Mie Univ, Tsu, Mie, Japan
[7] Kyushu Univ, Grad Sch Med Sci, Fukuoka, Japan
[8] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[9] Kurume Univ, Sch Med, Orthopaed Surg, Kurume, Fukuoka, Japan
[10] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[11] Chiba Canc Ctr, Chiba, Japan
[12] Teikyo Univ, Tokyo, Japan
[13] Sizuoka Canc Ctr, Shizuoka, Japan
[14] Nagoya Univ, Grad Sch, Nagoya, Aichi, Japan
[15] Nagoya Univ, Sch Med, Nagoya, Aichi, Japan
[16] Gifu Univ, Sch Med, Gifu, Japan
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Natl Canc Ctr Japan, Tokyo, Japan
[19] Okayama Univ, Grad Sch Med, Okayama, Japan
[20] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11504
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.
    Tanaka, Kazuhiro
    Machida, Ryunosuke
    Endo, Makoto
    Kawai, Akira
    Nakayama, Robert
    Tsukushi, Satoshi
    Asanuma, Kunihiro
    Hiraga, Hiroaki
    Hiraoka, Koji
    Yoshida, Shinichiro
    Yonemoto, Tsukasa
    Imanishi, Jungo
    Katagiri, Hirohisa
    Nishida, Yoshihiro
    Nagano, Akihito
    Sekino, Yuta
    Fukuda, Haruhiko
    Ozaki, Toshifumi
    Iwamoto, Yukihide
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A randomized phase II/III study, comparing perioperative adriamycin plus ifosfamide versus gemcitabine plus docetaxel for operable high grade soft tissue sarcomas in extremity or trunk: JCOG1306.
    Tanaka, Kazuhiro
    Kataoka, Kozo
    Mizusawa, Junki
    Yonemoto, Tsukasa
    Morioka, Hideo
    Hiraga, Hiroaki
    Chuuman, Hirokazu
    Ohno, Takatoshi
    Matsumine, Akihiko
    Abe, Satoshi
    Matuso, Kosuke
    Takahashi, Mitsuru
    Hiraoka, Koji
    Fukuda, Haruhiko
    Iwamoto, Yukihide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306
    Kataoka, Kozo
    Tanaka, Kazuhiro
    Mizusawa, Junki
    Kimura, Aya
    Hiraga, Hiroaki
    Kawai, Akira
    Matsunobu, Tomoya
    Matsumine, Akihiko
    Araki, Nobuhito
    Oda, Yoshinao
    Fukuda, Haruhiko
    Iwamoto, Yukihide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (08) : 765 - 769
  • [4] Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
    Kazuhiro Tanaka
    Ryunosuke Machida
    Akira Kawai
    Robert Nakayama
    Satoshi Tsukushi
    Kunihiro Asanuma
    Yoshihiro Matsumoto
    Hiroaki Hiraga
    Koji Hiraoka
    Munenori Watanuki
    Tsukasa Yonemoto
    Satoshi Abe
    Hirohisa Katagiri
    Yoshihiro Nishida
    Akihito Nagano
    Yoshiyuki Suehara
    Hiroyuki Kawashima
    Masanori Kawano
    Takeshi Morii
    Hiroshi Hatano
    Junya Toguchida
    Tomotake Okuma
    Masanobu Takeyama
    Satoshi Takenaka
    Toshihiro Akisue
    Taisuke Furuta
    Makoto Emori
    Toru Hiruma
    Hidetatsu Outani
    Tetsuji Yamamoto
    Tomoko Kataoka
    Haruhiko Fukuda
    Toshifumi Ozaki
    Yukihide Iwamoto
    British Journal of Cancer, 2022, 127 : 1487 - 1496
  • [5] Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
    Tanaka, Kazuhiro
    Machida, Ryunosuke
    Kawai, Akira
    Nakayama, Robert
    Tsukushi, Satoshi
    Asanuma, Kunihiro
    Matsumoto, Yoshihiro
    Hiraga, Hiroaki
    Hiraoka, Koji
    Watanuki, Munenori
    Yonemoto, Tsukasa
    Abe, Satoshi
    Katagiri, Hirohisa
    Nishida, Yoshihiro
    Nagano, Akihito
    Suehara, Yoshiyuki
    Kawashima, Hiroyuki
    Kawano, Masanori
    Morii, Takeshi
    Hatano, Hiroshi
    Toguchida, Junya
    Okuma, Tomotake
    Takeyama, Masanobu
    Takenaka, Satoshi
    Akisue, Toshihiro
    Furuta, Taisuke
    Emori, Makoto
    Hiruma, Toru
    Outani, Hidetatsu
    Yamamoto, Tetsuji
    Kataoka, Tomoko
    Fukuda, Haruhiko
    Ozaki, Toshifumi
    Iwamoto, Yukihide
    BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1487 - 1496
  • [6] Preoperative and Postoperative Chemotherapy with Ifosfamide and Adriamycin for Adult High-grade Soft-tissue Sarcomas in the Extremities: Japan Clinical Oncology Group Study JCOG0304
    Tanaka, Kazuhiro
    Kawamoto, Hiroshi
    Saito, Isamu
    Yoshimura, Kenichi
    Fukuda, Haruhiko
    Iwamoto, Yukihide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (04) : 271 - 273
  • [7] 10-year follow-up results of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG0304.
    Tanaka, Kazuhiro
    Mizusawa, Junki
    Naka, Norifumi
    Kawai, Akira
    Katagiri, Hirohisa
    Hiruma, Toru
    Matsumoto, Yoshihiro
    Tsuchiya, Hiroyuki
    Nakayama, Robert
    Hatano, Hiroshi
    Emori, Makoto
    Hosaka, Masami
    Yoshida, Yukihiro
    Okamoto, Takeshi
    Abe, Satoshi
    Asanuma, Kunihiro
    Yokoyama, Ryohei
    Fukuda, Haruhiko
    Ozaki, Toshifumi
    Iwamoto, Yukihide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study
    Hensley, Martee L.
    Enserro, Danielle
    Hatcher, Helen
    Ottevanger, Petronella B.
    Krarup-Hansen, Anders
    Blay, Jean-Yves
    Fisher, Cyril
    Moxley, Katherine M.
    Lele, Shashikant B.
    Lea, Jayanthi S.
    Tewari, Krishnansu S.
    Thaker, Premal H.
    Zivanovic, Oliver
    O'Malley, David M.
    Robison, Katina
    Miller, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3324 - +
  • [9] Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG030404.
    Tanaka, K.
    Mizusawa, J.
    Fukuda, H.
    Araki, N.
    Chuuman, H.
    Takahashi, M.
    Ozaki, T.
    Hiruma, T.
    Tsuchiya, H.
    Morioka, H.
    Morita, T.
    Wada, T.
    Hatori, M.
    Yoshida, Y.
    Toguchida, J.
    Abe, S.
    Matsumine, A.
    Yokoyama, R.
    Iwamoto, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304
    Tanaka, Kazuhiro
    Mizusawa, Junki
    Naka, Norifumi
    Kawai, Akira
    Katagiri, Hirohisa
    Hiruma, Toru
    Matsumoto, Yoshihiro
    Tsuchiya, Hiroyuki
    Nakayama, Robert
    Hatano, Hiroshi
    Emori, Makoto
    Watanuki, Munenori
    Yoshida, Yukihiro
    Okamoto, Takeshi
    Abe, Satoshi
    Asanuma, Kunihiro
    Yokoyama, Ryohei
    Hiraga, Hiroaki
    Yonemoto, Tsukasa
    Morii, Takeshi
    Ae, Keisuke
    Nagano, Akihito
    Yoshikawa, Hideki
    Fukuda, Haruhiko
    Ozaki, Toshifumi
    Iwamoto, Yukihide
    BMC CANCER, 2019, 19 (01)
12345